tiprankstipranks
Concert Pharma (CNCE)
NASDAQ:CNCE

Concert Pharma (CNCE) Technical Analysis

0 Followers

Technical Sentiment

Overall Consensus
Buy
15Bullish
1Neutral
6Bearish
Technical Analysis Consensus
Buy
6Bullish
1Neutral
3Bearish
Moving Average Consensus
Buy
9Bullish
0Neutral
3Bearish
Concert Pharma’s (CNCE) Moving Averages Convergence Divergence (MACD) indicator is 0.17, suggesting Concert Pharma is a Buy.
Concert Pharma’s (CNCE) 20-Day exponential moving average is 8.30, while Concert Pharma’s (CNCE) share price is $8.37, making it a Buy.
Concert Pharma’s (CNCE) 50-Day exponential moving average is 7.69, while Concert Pharma’s (CNCE) share price is $8.37, making it a Buy.

Concert Pharma (CNCE) Pivot Points

Jul 19, 2024, 01:14 AM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
8.10
8.22
8.30
8.42
8.50
8.62
8.70
Fibonacci
8.22
8.30
8.35
8.42
8.50
8.55
8.62
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Concert Pharma (CNCE) Moving Averages

Jul 19, 2024, 01:14 AM
Period
Simple
Exponential
MA5
8.37Buy
8.37Sell
MA10
8.38Sell
8.37Sell
MA20
8.37Buy
8.30Buy
MA50
7.71Buy
7.69Buy
MA100
6.40Buy
6.93Buy
MA200
6.04Buy
6.13Buy
Concert Pharma’s (CNCE) 10-Day exponential moving average is 8.37, while Concert Pharma’s (CNCE) share price is $8.37, making it a Sell.
Concert Pharma’s (CNCE) 100-Day exponential moving average is 6.93, while Concert Pharma’s (CNCE) share price is $8.37, making it a Buy.
Concert Pharma’s (CNCE) stock price is $8.37 and Concert Pharma’s (CNCE) 50-day simple moving average is 7.71, creating a Buy signal.
Concert Pharma’s (CNCE) stock price is $8.37 and Concert Pharma’s (CNCE) 100-day simple moving average is 6.40, creating a Buy signal.
Concert Pharma’s (CNCE) stock price is $8.37 and Concert Pharma’s (CNCE) 200-day simple moving average is 6.04, creating a Buy signal.

Concert Pharma (CNCE) Technical Indicators

Jul 19, 2024, 01:14 AM
Name
Value
Implied Action
RSI (14)
66.59
Neutral
STOCH (9,6)
12.20
Buy
STOCHRSI (14)
18.07
Buy
MACD (12,26)
0.17
Buy
ADX (14)
60.09
Sell
Williams %R
-85.71
Buy
CCI (14)
115.60
Sell
ATR (14)
0.14
-
Ultimate Oscillator
17.46
Sell
ROC
0.24
Buy
Concert Pharma’s (CNCE) Relative Strength Index (RSI) is 66.59, creating a Neutral signal.
Concert Pharma’s (CNCE) Trend Strength Indicator (ADX) is 60.09, creating a Sell signal.
Concert Pharma’s (CNCE) Commodity Channel Index (CCI) is 115.60, creating a Sell signal.
Concert Pharma’s (CNCE) Price Rate of Change (ROC) is 0.24, creating a Buy signal.

FAQ

Is CNCE a Buy, Hold, or Sell?
Based on CNCE’s technical indicators, CNCE is a Buy.
    What is CNCE’s RSI (14)?
    CNCE’s RSI (14) is 66.59, which suggests CNCE is a Neutral.
      What is CNCE’s MACD?
      CNCE’s MACD is 0.17, which suggests CNCE is a Buy.
        What is CNCE’s 5-day moving average?
        CNCE’s 5-day moving average is 8.37, which suggests CNCE is a Buy.
          What is CNCE’s 20-day moving average?
          CNCE 20-day moving average is 8.37, which suggests CNCE is a Buy.
            What is CNCE’s 50-day moving average?
            CNCE’s 50-day moving average is 7.71, which suggests CNCE is a Buy.
              What is CNCE’s 200-day moving average?
              CNCE’s 200-day moving average is 6.04, which suggests CNCE is a Buy.
                What is CNCE’s Williams % R (14)?
                CNCE’s Williams % R (14) is -85.71, which suggests CNCE is a Buy.
                  What is CNCE’s CCI (14)?
                  CNCE’s CCI (14) is 115.60, which suggests CNCE is a Sell.
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis